We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Point-of-Care HIV Assay To Be Sold in Latin America

By HospiMedica staff writers
Posted on 13 Aug 2007
A rapid, in-vitro, qualitative test detects antibodies to human immunodeficiency virus type 1 (HIV-1) in human whole blood, serum, or plasma. More...
The test is capable of providing results in 60-seconds and is intended for use as a screening assay by trained personnel in medical facilities, clinical laboratories, emergency care situations, and physicians' offices.

Called Insti HVI-1, the test was developed by a Canadian company called bioLytical (Vancouver). After completion of a lengthy approval process, the company has received final licensing approval to sell and distribute the Insti kit in Venezuela and Mexico.

Latin America has attributed its high HIV transmission rates to common factors including widespread poverty and migration, and a lack of education and awareness, said Matthew Clayton, chief operating officer, bioLytical. This approval is an important and necessary first step to provide the countries in this region with access to rapid HIV testing.

The president and CEO of BioLytical, Carl Roy added, Mexico and Venezuela are leading the way in Latin America by bringing this diagnostic testing to their citizens. We are in discussions with other countries in this region, and we are optimistic the Insti Kit will be available in more countries in the near future.


Related Links:
bioLytical

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Medical-Grade Display
HL2316SHTB
Syringe Pump
SP50 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.